A Phase Ib Study Combining Irinotecan With AZD1775 a Selective Wee 1 Inhibitor in RAS (KRAS or NRAS) or BRAF Mutated Metastatic Colorectal Cancer Patients Who Have Progressed on First Line Therapy
Brief description of study
If you have been diagnosed with colon cancer, you may qualify for this clinical trial. The goal of this phase Ib dose-escalation study is to determine whether combination therapy of Irinotecan with AZD1775 is safe and effective in treating RAS/Raf-mutated metastatic colorectal cancer patients. This study will also determine what effect the investigational drug, AZD1775 and Irinotecan has on you and your disease and determine the amount of drug levels in your body over time, which is known as pharmacokinetic (PK) testing.